Today iCoat Medical releases the company´s first public interim report for the period january-june 2022. Press […]
Malmö, August 10th, 2022 – iCoat Medical AB (publ.), a clinical-stage pharmaceutical company developing novel therapeutics […]
An annual general meeting (“AGM”) in iCoat Medical AB (publ), corp. reg. no 559172-8208 (the “Company”) […]
iCoat Medical has been given the opportunity to present its preclinical data of TUM012 at the […]
iCoat Medical has been given the opportunity to present our research at the 29th International Congress […]
The shareholders in iCoat Medical AB (publ), corporate registration number 559172-8208 (the “Company”) are hereby convened […]
Press release 16 May 2022 iCoat Medical publishes Annual Report 2021. iCoat Medical today publishes its […]
Today, iCoat Medical welcomes Göran Lerenius as its General Counsel. As iCoat Medical is progressing its […]
On April 19th, Njurfonden published an interview with iCoat Medical’s Chief Medical Officer Alireza Biglarnia highlighting […]
Today, iCoat Medical announces that the European Commission has issued a positive decision on the company’s […]